Ionis Pharmaceuticals

Ionis Pharmaceuticals invented antisense oligonucleotide (ASO) technology and has the broadest RNA-targeting drug pipeline in the industry, with approved medicines for spinal muscular atrophy, transthyretin amyloidosis, and several rare neurological diseases. Founded at the intersection of chemistry and molecular biology, Ionis maintains deep ties to Scripps Research Institute, UC San Diego, and Cold Spring Harbor Laboratory, where early antisense chemistry was validated. Its Academic Drug Discovery program partners with university neuroscience and cardiology departments to identify novel RNA targets and provide ASO tool compounds for basic research, creating a co-discovery pipeline that generates both publishable science and proprietary leads. Ionis actively recruits from RNA biology, medicinal chemistry, and bioinformatics PhD programs, particularly from programs at MIT, Stanford, and the Broad Institute. The company is one of the clearest examples of university-originated technology becoming a multi-billion-dollar commercial platform.